USMLE forum
 
USMLE Forum
Step 1
Step 2 CK
Step 2 CS
Matching & Residency
Step 3
Classifieds
 
Archives
 
 
  <<   < *  Step 1   *  >   >>  

* Crazy1
 #846104  
  shinenrise - 12/06/17 12:34
 
  A study is designed to evaluate the efficacy of a new drug, KM28. The study will compare KM28 plus standard care versus standard care alone with regard to decreasing the incidence of recurrent breast cancer. The Federal Drug Administration (FDA) will approve the new drug if KM28 plus standard care decreases the rate of breast cancer recurrence by at least 40% compared to standard therapy alone. The recurrence rate on standard therapy is found to be 8%. In order for the FDA to approve KM28, what is the maximal incidence of recurrent disease acceptable for women treated with KM28 plus standard therapy?

A. 2.8%
B. 3.2%
C. 3.6%
D. 4.8%
E. 5.2%
 
Report Abuse

 
 

* Re:Crazy1
#3354493
  anasteps - 12/06/17 19:35
 
  I dnt anything in biostats. Lol  
Report Abuse

* Re:Crazy1
#3354494
  sawtooth - 12/06/17 19:36
 
  D
 
Report Abuse

* Re:Crazy1
#3354498
  roshank06 - 12/06/17 20:50
 
  I got D.

.08 - (.08 x .4)
 
Report Abuse

* Re:Crazy1
#3354506
  shinenrise - 12/07/17 01:04
 
  new drug if KM28 plus standard care decreases the rate of breast cancer recurrence by at least 40% compared to standard therapy alone.--- >40% of 8% - 3.2
and maximum acceptable recurrence rate - > 8-3.2 % = 4.8%

OR other way:

maximum acceptable recurrence is 60% of 8%===> 4.8%

there is one more way but that looks so complicated ,just like question.(calculate RRR)

hence D is the correct ans.

Good job! sawtooth and roshank. thank you.
 
Report Abuse

          Page 1 of 1          

[<<First]   [<Prev]  ... Message ...  [Next >]   [Last >>]

 
Logon to post a new Message/Reply
 
 
 
 

 

 

Google
  Web USMLEforum.com
 

Step 1 Step 2 CK Step 2 CS Matching & Residency Step 3 Classifieds
LoginUSMLE LinksHome